On May 7, 2026, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) reported Q1 EPS of 0c, versus the consensus estimate of (4c).
Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) is one of the best fast growing penny stocks to buy according to analysts. On January 14, Citi analyst Yigal Nochomovitz increased the price target for ...
25d
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
SONATA-HCM anticipated to be fully enrolled mid-2026 Resubmission of NDA for ZYNQUISTA ® in type 1 diabetes anticipated mid-2026 with potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results